Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro

Infection, Supplement

Volumn 33, Issue 2, 2005, Pages 50-54

  Ulrich, Martina ^a   Berger, J ^b   Moller J G ^c   Doring G ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MAX PLANCK INSTITUTE FOR DEVELOPMENTAL BIOLOGY   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIBIOTIC AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONCENTRATION; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; NOSE POLYP; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; BACTERIAL INFECTION; BACTERIAL STRAIN; CELL GROWTH; CELL VACUOLE; DRUG ACCUMULATION; DRUG EFFECT; EPITHELIUM CELL; NONHUMAN; PROVOCATION TEST;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CELLS, CULTURED; CIPROFLOXACIN; EPITHELIAL CELLS; HAEMOPHILUS INFLUENZAE; HUMANS; PSEUDOMONAS AERUGINOSA; QUINOLINES; RESPIRATORY SYSTEM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 31444436995     PISSN: 01732129     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-8208-9     Document Type: Article

References (27)

1. Statistisches Bundesamt: Gesundheitsbericht für Deutschland (1998) 234-236.
2. Nolte D: Epidemiologie. In: Konietzko N (ed): Bronchitis. Urban und Schwarzenberg, München 1995, 37-51.
3. Farrell DJ, Jenkins SG: Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROJEKT US 2001-2002. J Antimicrob Chemother 2004; 54: 17-22.
4. Dalhoff A, Krasemann C, Wegener S, Tillotson G: Penicillin-resistant Streptococcus pneumoniae: review of moxifloxacin activity. Clin Infect Dis 2001; 32: 22-29.
5. Reinert RR, Lutticken R, Reinert S, Al-Lahham A, Lemmen S: Antimicrobial resistance of Streptococcus pneumoniae isolates of outpatients in Germany, 1999-2000. Chemotherapy 2004; 50: 184-189.
6. Zetola N, Francis JS, Nuermberger EL, Bishai WR: Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005; 5: 275-286.
7. Shah AA, Hasan F, Ahmed S, Hameed A: Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases. Res Microbiol 2004; 155: 409-421.
8. Doern GV: Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance. Otolaryngol Head and Neck Surgery 2002; 127 (Suppl.): S17-23.
9. Landen H, Moller M, Tillotson GS, Kubin R, Hoffken G: Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 2001; 29: 51-60.
10. Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, Hoffken G: Effectiveness of oral moxifloxacin in standard firstline therapy in community-acquired pneumonia. Eur Respir J 2003; 21: 135-143.
11. n. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, Sagnier PP: Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964.
12. Faich GA, Morganroth J, Whitehouse AB, Brar JS, Arcuri P, Kowalsky SF, Haverstock DC, Celesk RA, Church DA: Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004; 38: 749-754.
13. Lorenz J, Busch W, Thate-Waschke IM: Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. J Int Med Res 2001; 29: 61-73.
14. Grossman RF: The role of fluoroquinolones in respiratory tract infections. J Antimicrobial Chemother 1997; 40 (Suppl. A): 59-62.
15. Grossman R, Mukherjee J, Vaughan D, Eastwood C, Cook R, La Forge J, Lampron N: A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. Chest 1998; 113: 131-141.
16. Muller M, Stass H, Brunner M, Moller JG, Lackner E, Eichler HG: Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-2349.
17. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R: Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibreoptic bronchoscopy. J Antimicrob Chemother 1999; 44: 835-838.
18. Wise R, Andrews JM, Marshall G, Hartman G: Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999; 43: 1508-1510.
19. Wise R, Honeybourne D: Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999; 14: 221-229.
20. Wirtz M, Kleeff J, Swoboda S, Halaceli I, Geiss HK, Hoppe-Tichy T, Buchler MW, Friess H: Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875-877.
21. Mandell GL, Coleman E: Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001; 45: 1794-1798.
22. Paillard D, Grellet J, Dubois V, Saux MC, Quentin C: Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model. Antimicrob Agents Chemother 2002; 46: 288-293.
23. Pascual A, Garcia I, Ballesta S, Perea E-J: Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1999; 43: 12-15.
24. Ulrich M, Herbert S, Berger J, Bellon G, Louis D, Münker G, Döring G: Localization of Staphylococcus aureus in infected airways of patients with cystic fibrosis and in a cell culture model of S. aureus adherence. Am J Respir Cell Mol Biol 1998; 19: 83-91.
25. Ulrich M, Döring G: Three-dimensional human airway epithelial cell cultures. J Cystic Fibrosis 2004; 3 (Suppl. 1): 55-57.
26. Talbot UM, Paton AW, Paton JC: Uptake of Streptococcus pneumoniae by respiratory epithelial cells. Infect Immun 1996; 64: 3772-3777.
27. Ulrich M, Albers C, Möller J-G, Dalhoff A, Korfmann G, Künkele F, Döring G: Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against Streptococcus pneumoniae in vitro when administered up to 6 hours after challenge. Antimicrob Agents Chemother 2005; 49: 5119-5122.